Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

Trial Profile

European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rufinamide (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 06 Dec 2016 Results (n=24) assessing long-term safety in adult patients, presented at the 70th Annual Meeting of the American Epilepsy Society
    • 06 Dec 2016 Final results from a European registry study, presented at the 70th Annual Meeting of the American Epilepsy Society
    • 12 Sep 2016 According to an Eisai media release, final results (n=11) were presented at the 12th European Congress on Epileptology (ECE) 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top